Anupam Rasayan India Ltd (BOM:543275)
1,151.45
+21.05 (1.86%)
At close: Oct 28, 2026
Anupam Rasayan India Revenue
Anupam Rasayan India had revenue of 6.55B INR in the quarter ending June 30, 2026, with 34.82% growth. This brings the company's total for the last twelve months to 25.35B, up 51.90% year-over-year. In the fiscal year ending March 31, 2026, Anupam Rasayan India had annual revenue of 23.65B with 64.61% growth.
Revenue (ttm)
25.35B
Revenue Growth
+51.90%
P/S Ratio
5.17
Revenue / Employee
10.13M
Employees
2,501
Market Cap
131.08B
Revenue by Geography
- India 19.47B 82.3%
- Export 3.61B 15.3%
- Unallocated 574.89M 2.4%
Fiscal year ended Mar 31, 2026 See the full Anupam Rasayan India breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 23.65B | 9.28B | 64.61% |
| Mar 31, 2025 | 14.37B | -380.95M | -2.58% |
| Mar 31, 2024 | 14.75B | -1.27B | -7.92% |
| Mar 31, 2023 | 16.02B | 5.28B | 49.19% |
| Mar 31, 2022 | 10.74B | 2.58B | 31.59% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BASF India | 160.27B |
| PCBL Chemical | 85.49B |
| Galaxy Surfactants | 57.52B |
| Jubilant Ingrevia | 49.21B |
| Anupam Rasayan India | 25.35B |
| Fine Organic Industries | 24.72B |
| Acutaas Chemicals | 15.74B |
| Aether Industries | 12.30B |
Anupam Rasayan India News
- 2 months ago - Anupam Rasayan India Transcript: Q1 26/27 - Transcripts
- 2 months ago - Anupam Rasayan India Quarterly report: Q1 2027 - Filings
- 2 months ago - Anupam Rasayan India Slides: Q1 2027 - Filings
- 4 months ago - Anupam Rasayan India commercialises ETFA using flow chemistry, a global first - Business Upturn
- 4 months ago - Anupam Rasayan makes Rs 299 per share open offer for Bliss GVS Pharma - Business Upturn
- 4 months ago - Bliss GVS Pharma faces Rs 299 per share open offer from Anupam Rasayan - Business Upturn
- 5 months ago - Anupam Rasayan India Transcript: Q4 25/26 - Transcripts
- 5 months ago - Anupam Rasayan India Annual report: Q4 2026 - Filings